NMDAR inhibition-independent antidepressant actions of ketamine metabolites

[1]  G. Aghajanian,et al.  Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants , 2016, Nature Medicine.

[2]  J. Potash,et al.  Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. , 2015, The American journal of psychiatry.

[3]  R. Schwarcz,et al.  The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[4]  K. Hashimoto,et al.  R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects , 2015, Translational Psychiatry.

[5]  Judith E. Hall,et al.  Evidence that Subanesthetic Doses of Ketamine Cause Sustained Disruptions of NMDA and AMPA-Mediated Frontoparietal Connectivity in Humans , 2015, The Journal of Neuroscience.

[6]  M. Sanghvi,et al.  The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats , 2015, Pharmacology research & perspectives.

[7]  P. Pitychoutis,et al.  Sex differences in the rapid and the sustained antidepressant-like effects of ketamine in stress-naïve and “depressed” mice exposed to chronic mild stress , 2015, Neuroscience.

[8]  M. Banasr,et al.  BDNF Release Is Required for the Behavioral Actions of Ketamine , 2014, The international journal of neuropsychopharmacology.

[9]  J. Roiser,et al.  Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression , 2014, Translational Psychiatry.

[10]  E. Nestler,et al.  Effects of Striatal ΔFosB Overexpression and Ketamine on Social Defeat Stress–Induced Anhedonia in Mice , 2014, Biological Psychiatry.

[11]  S. Chaki,et al.  Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats , 2014, Behavioural Brain Research.

[12]  T. Gant.  Using deuterium in drug discovery: leaving the label in the drug. , 2014, Journal of medicinal chemistry.

[13]  A. Keller,et al.  Adolescent Cannabinoid Exposure Permanently Suppresses Cortical Oscillations in Adult Mice , 2013, Neuropsychopharmacology.

[14]  Dan V Iosifescu,et al.  Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. , 2013, The American journal of psychiatry.

[15]  M. Kabbaj,et al.  Sex differences in the antidepressant-like effects of ketamine , 2013, Neuropharmacology.

[16]  C. Zarate,et al.  Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors. , 2013, European journal of pharmacology.

[17]  M. Torjman,et al.  Stereoselective and regiospecific hydroxylation of ketamine and norketamine , 2012, Xenobiotica; the fate of foreign compounds in biological systems.

[18]  G. Laje,et al.  Relationship of Ketamine's Plasma Metabolites with Response, Diagnosis, and Side Effects in Major Depression , 2012, Biological Psychiatry.

[19]  S. Chaki,et al.  Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression , 2011, Behavioural Brain Research.

[20]  E. Kavalali,et al.  NMDA Receptor Blockade at Rest Triggers Rapid Behavioural Antidepressant Responses , 2011, Nature.

[21]  Sean Parkin,et al.  (S)-1-(2-Chlorophenyl)-2-oxocyclohexan-1-aminium d-tartrate , 2011, Acta crystallographica. Section E, Structure reports online.

[22]  Nanxin Li,et al.  mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists , 2010, Science.

[23]  D. Luckenbaugh,et al.  A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. , 2010, Archives of general psychiatry.

[24]  J. Crawley,et al.  The Female Urine Sniffing Test: A Novel Approach for Assessing Reward-Seeking Behavior in Rodents , 2010, Biological Psychiatry.

[25]  Bijan Pesaran,et al.  Chronux: a platform for analyzing neural signals , 2009, BMC Neuroscience.

[26]  Guang Chen,et al.  Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors , 2008, Biological Psychiatry.

[27]  D. Kupfer,et al.  Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report , 2006 .

[28]  Paul J Carlson,et al.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. , 2006, Archives of general psychiatry.

[29]  M. Whittington,et al.  Gamma Oscillations Induced by Kainate Receptor Activation in the Entorhinal Cortex In Vitro , 2003, The Journal of Neuroscience.

[30]  Olga V. Demler,et al.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). , 2003, JAMA.

[31]  J. de Vry,et al.  Role of the NMDA receptor NR2B subunit in the discriminative stimulus effects of ketamine , 2003, Behavioural pharmacology.

[32]  R. Traub,et al.  Inhibition-based rhythms: experimental and mathematical observations on network dynamics. , 2000, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[33]  John H Krystal,et al.  Antidepressant effects of ketamine in depressed patients , 2000, Biological Psychiatry.

[34]  J. Reynolds,et al.  Chronic ethanol exposure alters MK-801 binding sites in the cerebral cortex of the near-term fetal guinea pig. , 1999, Alcohol.

[35]  F. M. Borgbjerg,et al.  Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. , 1997, European journal of pharmacology.

[36]  M. Nomoto,et al.  Involvement of N-methyl-D-aspartate (NMDA) receptors in noncompetitive NMDA receptor antagonist-induced hyperlocomotion in mice , 1995, Pharmacology Biochemistry and Behavior.

[37]  T. Baillie,et al.  Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine. , 1986, Journal of medicinal chemistry.

[38]  J. Davisson,et al.  Stereochemical studies of demethylated ketamine enantiomers. , 1982, Journal of pharmaceutical sciences.

[39]  T. Baillie,et al.  Studies on the biotransformation of ketamine. 1-Identification of metabolites produced in vitro from rat liver microsomal preparations. , 1981, Biomedical mass spectrometry.

[40]  C. Morgan,et al.  Ketamine use: a review. , 2012, Addiction.

[41]  B. Lebowitz,et al.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. , 2006, The American journal of psychiatry.